(Hepatology

(Hepatology GSK3 inhibitor 2014;60:408-418) “
“Although prolonged lamivudine (LAM) therapy is associated with the emergence of LAM-resistant mutations, it is still a commonly used therapy in many Asian countries because of its established long-term safety and low cost. The aim of our study was to assess the predictors of long-term LAM treatment response and to establish an individual prediction model (IPM) for hepatitis B virus e antigen (HBeAg) seroconversion

in HBeAg-positive chronic hepatitis B (CHB) patients. This was a multicenter analysis of 838 patients treated with LAM between January 1999 and August 2004. Of these, 748 patients were followed up for at least 24 months. The median age was 43.0 years (range, 19–79 years) and the mean duration of LAM monotherapy was 34.2 ± 0.7 months. In the multivariate analysis, age (odds ratio [OR] = 0.974, P < 0.001), baseline alanine aminotransferase level (OR = 1.001, P = 0.014), and baseline hepatitis B virus DNA level (OR = 0.749, P < 0.001) were independent factors for HBeAg seroconversion. Based on the predictors, an IPM was established. Patients were classified into high (> 50%), intermediate (30–50%), or low (≤ 30%) response groups based on their probability

of HBeAg seroconversion Selleck BMS-777607 according to the IPM. The cumulative HBeAg seroconversion rate at 6 years for the high, intermediate, and low response groups was 66.0%, 48.5%, and 21.8%, respectively (P < 0.001). An IPM was developed based on predictors of HBeAg seroconversion in HBeAg-positive CHB patients on LAM monotherapy. This model will allow screening

of LAM responders prior to the commencement of antiviral treatment. “
“Objective and Background:  Gastrointestinal symptoms are quite common among the general population, but different survey methods show different epidemiology, and the effect of psychosocial and behavioral factors on the symptoms have been studied mainly by the subgroup selleck chemical The aims of this studies are; 1: to clarify the difference of the survey methods on the epidemiology of FGID symptoms, 2: correlation with psycho-behavioral background in symptomatic subjects. Methods:  Questionnaires focused on GI symptoms and psycho-behavioral background were generated. Questionnaires were sent via e-mail and postal mail to the members of the registered panel. Results:  A total of 2125 and 11 020 responses were recovered from electronic survey and postal survey. Significant difference in the prevalence of GI symptoms, 47% in electronic survey and 25% in postal survey, were observed. Despite the difference in the prevalence, the proportions of symptom subtypes and the patterns of the overlaps were similar in the two methods. In the analysis of the effect of psycho-behavioral factors, this study showed that those who have higher level of psycho-behavioral problem had higher prevalence of GERD, FD and IBS symptoms.

Comments are closed.